Taft Chicago partners Steve Auten and Roshan Shrestha, Ph.D. will speak on “Critical Updates in U.S. Patent Litigation: Key Cases and Strategic Implications for Pharma & Biotech” at the IpEssentia webinar on Nov. 11 at 10:00 p.m. CST (Nov. 12 at 9:30 a.m. IST). The program will cover comprehensive insights into significant legal cases and emerging trends in the pharmaceutical industry involving skinny labeling and carve-outs, clinical trial disclosures and patent validity, and more.

To register, please click here.

Auten chairs Taft’s Pharmaceutical & Life Sciences Litigation group and is a member of Taft’s Executive Committee. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators, and others on his LinkedIn blog “Hatch Waxman ANDA Litigation Forum” or HALF, which has over 14,000 members worldwide. Auten regularly represents clients in the areas of Paragraph IV design strategies, Hatch-Waxman litigation, and biosimilar market opportunities.

Shrestha focuses his practice on intellectual property law, including patent litigation, prosecution, and opinion work in the chemical, pharmaceutical, and electronic material arts. He has broad litigation experience, including district court litigation, contested AIA proceedings, e.g., Re-examination and Inter Partes Review (IPR) at the Patent Trial and Appeal Board (PTAB) in the United States Patent and Trademark Office (USPTO), International Trade Commission (ITC), and appellate matters.